Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Cancer02:18

Cancer

53.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patterns of vitamin D deficiency and functional resistance in cancer: a brief observational report.

Frontiers in molecular biosciences·2026
Same author

Integrative oncology along with systemic cancer therapies in advanced bladder and prostate cancer: metabolic optimization guiding the shift from palliative care to clinical remission - a case report.

Frontiers in oncology·2026
Same author

The cellular stress sensor HSPB1 regulates the membrane localization of amino acid transporter SLC7A5 in breast cancer.

The Journal of biological chemistry·2026
Same author

Assessing Blood Pressure, Mental Health, and HRV Responses to Integrated Acupuncture in Hypertensive Patients: A Pilot Randomized Controlled Trial.

Medical acupuncture·2026
Same author

Sleep hygiene and sleep quality among yoga and naturopathy medical students in India: a multisite cross-sectional study.

Frontiers in sleep·2025
Same author

Exploring the anticancer potential of traditional herbs from Tamil Nadu: a narrative review of ethnomedicinal insights and scientific evidence.

Frontiers in immunology·2025

Related Experiment Video

Updated: Jan 9, 2026

Extraction of Aqueous Metabolites from Cultured Adherent Cells for Metabolomic Analysis by Capillary Electrophoresis-Mass Spectrometry
11:39

Extraction of Aqueous Metabolites from Cultured Adherent Cells for Metabolomic Analysis by Capillary Electrophoresis-Mass Spectrometry

Published on: June 9, 2019

9.6K

Decoding metabolic dysfunction in cancer: foundations for early detection and personalized therapeutics.

Pradeep M K Nair1, Ayyappan Palanisamy1, Sekar Sivaranjani1

  • 1Department of Integrative Oncology, Mirakle Integrated Health Centre, Pollachi, India.

Frontiers in Endocrinology
|December 10, 2025
PubMed
Summary

Metabolic dysfunction, not just genetics, may precede cancer. Key metabolic markers could help predict cancer risk and guide early interventions for better outcomes.

Keywords:
cancer riskearly detectionepigenetic regulationintegrative oncologymetabolic markers

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.5K
Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.0K

Related Experiment Videos

Last Updated: Jan 9, 2026

Extraction of Aqueous Metabolites from Cultured Adherent Cells for Metabolomic Analysis by Capillary Electrophoresis-Mass Spectrometry
11:39

Extraction of Aqueous Metabolites from Cultured Adherent Cells for Metabolomic Analysis by Capillary Electrophoresis-Mass Spectrometry

Published on: June 9, 2019

9.6K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.5K
Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.0K

Area of Science:

  • Integrative Oncology
  • Cancer Biology
  • Metabolic Medicine

Background:

  • Cancer's global burden necessitates novel prevention and detection strategies.
  • Emerging evidence implicates metabolic dysfunction as a precursor to cancer, beyond traditional genetic focus.
  • Metabolic alterations like disrupted glucose, amino acid, and lipid metabolism contribute to cancer development via oxidative stress and immune evasion.

Purpose of the Study:

  • To explore the role of metabolic dysfunction in cancer development.
  • To identify key metabolic markers as potential early indicators of cancer risk.
  • To discuss the utility of metabolic markers in integrative oncology for prediction and prognosis.

Main Methods:

  • Review of scientific literature on metabolic pathways in cancer.
  • Discussion of specific metabolic markers including homocysteine, lactate dehydrogenase (LDH), HbA1c, insulin, cortisol, neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), vitamin B12, parathyroid hormone (PTH), ionized calcium, estrogen, and progesterone.
  • Integration of insights from integrative oncology practice.

Main Results:

  • Metabolic markers such as homocysteine, LDH, HbA1c, insulin, cortisol, NLR, CRP, vitamin B12, PTH, ionized calcium, estrogen, and progesterone show potential as early cancer risk indicators.
  • These markers, when considered collectively, highlight interconnected biochemical pathways fostering tumorigenesis.
  • Metabolic markers can serve as predictive and prognostic tools, complementing genetic and imaging diagnostics.

Conclusions:

  • Metabolic dysfunction is a critical factor in cancer development and progression.
  • Early identification and monitoring of metabolic markers can enable timely interventions to mitigate cancer risk.
  • Further multicentric data are required to validate the translational utility of these metabolic markers in diverse clinical settings.